GnRH receptor

Argtide is a luteinizing hormone-releasing hormone (LHRH) antagonist that effectively inhibits the release of gonadotropins. This compound is utilized in research related to endometriosis and hormone-sensitive cancers, providing valuable insights into therapeutic strategies and mechanisms of action. Its role in modulating LHRH signaling pathways makes it an important tool for studying reproductive and oncological health.

Federelin is a gonadotropin-releasing hormone (GnRH) analog that acts by binding to GnRH receptors to stimulate the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This compound plays a significant role in reproductive biology and is used in research applications involving hormonal regulation, fertility studies, and endocrine system investigations. Its ability to modulate hormone levels makes it a valuable tool in studying reproductive health and related disorders.

ORG 30276 is a potent GnRH receptor antagonist that effectively inhibits gonadotropin secretion by reducing serum LH and FSH levels. It decreases the expression of unoccupied pituitary GnRH receptors, resulting in significant downregulation of gonadotropin beta-subunit mRNA in the pituitary gland. The modulatory effects of ORG 30276 on gonadotropin dynamics can be selectively reversed by the administration of specific sex steroids, particularly androgens, which notably influence FSH beta-subunit mRNA levels. This compound is valuable for research in reproductive biology and endocrine regulation.

[Ala6]-LHRH is a synthetic analog of luteinizing hormone-releasing hormone (GnRH) that functions as a potent agonist for GnRH receptors. This compound effectively stimulates the secretion of luteinizing hormone from the pituitary gland, thereby enhancing reproductive hormone regulation. [Ala6]-LHRH is instrumental in fertility treatments and plays a significant role in managing conditions associated with hormone imbalances.

Histrelin is a GnRH receptor agonist that functions by stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to elevated testosterone levels. This compound serves as a valuable tool in research related to prostate cancer and endometriosis by modulating hormonal pathways. Histrelin's ability to influence reproductive hormone levels makes it instrumental in exploring treatments for hormone-dependent conditions.

(D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH), targeting the LHRH receptor. This compound enhances the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), playing a crucial role in regulating reproductive functions. It is valuable for research applications focused on reproductive biology and hormone signaling pathways.

Elagolix is a selective, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRH receptor) with a dissociation constant (KD) of 54 pM. This compound exhibits potent biological activity in modulating hormonal signaling and is primarily utilized in research focused on endometriosis-related pain mechanisms. Its ability to inhibit NFAT pathways further expands its potential applications in investigating reproductive health and endocrine disorders.

LH-RH (4-10) is a heptapeptide derived from luteinizing hormone-releasing hormone (LHRH) through enzymatic degradation in the pituitary and hypothalamus. This peptide plays a crucial role in the regulation of gonadotropin secretion and is known to influence reproductive functions. LH-RH (4-10) is valuable in research applications including studies on hormonal regulation, reproductive physiology, and neuroendocrine signaling pathways.

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a potent Luteinizing-hormone-releasing hormone (LHRH) analogue that functions as a GnRH receptor antagonist. This compound demonstrates significant activity in inhibiting luteinizing hormone release, making it valuable for research in reproductive biology and endocrinology. Its application extends to studies investigating hormone regulation and potential therapeutic interventions in hormone-sensitive conditions.

[D-Phe2,6, Pro3]-LH-RH is a potent luteinizing hormone-releasing hormone (LHRH) antagonist that effectively inhibits the action of LHRH. This compound plays a critical role in regulating reproductive physiology by blocking the secretion of luteinizing hormone and follicle-stimulating hormone. It is widely used in research applications focused on hormone regulation, reproductive biology, and the study of pituitary function.

Onvitrelin ucalontide is an analogue of luteinizing hormone-releasing hormone (LHRH) that demonstrates antineoplastic activity. This peptide, with the sequence KFAKFAKKFAKFAKKFAKQHWSYGLRPG, has been shown to effectively inhibit the growth of breast cancer, ovarian cancer, and prostate cancer xenografts in mouse models. Its application in cancer research provides insights into hormonal regulation and therapeutic strategies targeting LHRH pathways.

GnRH Antagonist 3 is a potent gonadotropin-releasing hormone (GnRH) antagonist, exhibiting an IC50 value of 7 nM. This compound effectively inhibits GnRH activity, making it a valuable tool for research into hormone-dependent diseases. Its use may extend to studies in reproductive biology and the development of therapeutics targeting GnRH-related conditions.

[D-pGlu1,D-Phe2,D-NaI3,6]-Gn-RH is a potent gonadotropin-releasing hormone (GnRH) receptor agonist. This compound exhibits dose-dependent inhibition of progesterone secretion from cultured human granulosa cells, making it a valuable tool for studying reproductive hormone regulation. Its applications extend to research in reproductive biology and endocrinology, providing insights into GnRH signaling mechanisms.

Azaline is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, exhibiting a KD value of 0.48 nM. It effectively induces histamine release, comparable to GnRH, and can completely inhibit ovulation in female rats at doses of 2.0-3.0 μg. Azaline holds potential applications in the investigation of reproductive functions and hormonal regulation.

Elagolix-d9 is a deuterium-labeled version of Elagolix, a selective, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist with a binding affinity (KD) of 54 pM. This stable isotope is valuable for studies related to endometriosis-associated pain, enabling researchers to track metabolic pathways and enhance understanding of GnRH receptor modulation. Elagolix-d9 serves as a useful tool for elucidating the mechanisms of action and therapeutic potential in reproductive health research.

Lamprey LH-RH I is a gonadotropin-releasing hormone (GnRH) that primarily stimulates the release of gonadotropins. It induces an increase in plasma steroid levels and facilitates ovulation in lampreys, demonstrating specific biological activity in this model organism. This compound is useful for studies focused on reproductive physiology and endocrine regulation in aquatic vertebrates.

Fertirelin acetate is a gonadotropin-releasing hormone (GnRH) analog that primarily targets the GnRH receptor. It is involved in regulating reproductive hormone secretion and is used in research to study the reversal of follicular cysts in cows. This compound serves as an important tool for investigating reproductive health and management in veterinary science.

A-75998 is a luteinizing hormone-releasing hormone (LHRH) antagonist that inhibits the action of LHRH at its receptor. This compound is primarily utilized in the study of hormone-sensitive cancers and endometriosis, where modulation of LHRH signaling may provide therapeutic benefits. Its ability to disrupt hormone signaling pathways makes it a valuable reagent for research into treatments targeting these conditions.

WAY-207024 is an orally active antagonist of the gonadotropin-releasing hormone receptor (GnRH-R), exhibiting an IC50 of 12 nM for human GnRH and 71 nM for rat GnRH. This compound effectively inhibits luteinizing hormone (LH) release in rats, with an IC50 of 350 nM, and significantly reduces plasma LH levels following oral administration. WAY-207024 is a valuable tool for research into reproductive biology and potential therapeutic interventions targeting hormonal regulation.

Acyline is a GnRH antagonist that effectively inhibits gonadotropin release, leading to decreased testosterone levels. Its primary mechanism involves blocking the GnRH receptor, making it valuable in studies of hormonal regulation and reproductive biology. Acyline is widely used in research applications focused on fertility control, hormone-dependent diseases, and endocrine disruption.

WAY-207024 dihydrochloride is a potent antagonist of the gonadotropin-releasing hormone receptor (GnRH-R), exhibiting an IC50 of 12 nM for human GnRH and 71 nM for rat GnRH. This compound effectively inhibits the release of luteinizing hormone (LH) in rats, with an IC50 of 350 nM. WAY-207024 dihydrochloride is useful for studying the regulation of reproductive hormones and exploring therapeutic strategies for disorders related to GnRH signaling.

(D-His2)-Goserelin is a peptide analog derived from Goserelin, which mimics the structure of gonadotropin-releasing hormone (GnRH/LHRH). This compound serves primarily as an agonist of GnRH receptors, influencing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Its biological activity makes it valuable in research focused on reproductive biology, endocrinology, and fertility treatments.

LH-RH (7-10) targets the gonadotropin-releasing hormone (GnRH) pathway and serves as a significant degradation product of luteinizing hormone-releasing hormone. This tetrapeptide is produced by macrophages and type I and type II pneumocytes, playing a role in various physiological processes. Its applications in research include studies on reproductive health and endocrine regulation.

Azaline B is a potent antagonist of gonadotropin-releasing hormone (GnRH) with an IC50 of 1.37 nM. This compound exhibits significant biological activity in modulating reproductive hormone pathways, making it valuable for research into sex hormone-related disorders, ovulation induction, and male contraception. Its specificity and potency position Azaline B as a crucial tool for advancing the understanding of reproductive biology and therapeutic interventions in related pathological states.

(D-Tyr5,D-Ser(tBu)6,Azagly10)-LHRH is a luteinizing hormone-releasing hormone (LHRH) analogue that functions by mimicking the natural hormone to regulate reproduction. It stimulates the secretion of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH), making it significant for research on reproductive endocrinology. This compound can be utilized in studies investigating various aspects of reproductive health and hormonal regulation.

(D-His(Bzl)6)-LHRH (1-7) free acid is a synthetic derivative of luteinizing hormone-releasing hormone (LHRH) that features modifications to enhance stability and biological activity. By incorporating unnatural amino acids, this peptide exhibits improved half-life and reduced metabolism, facilitating increased efficacy in inhibiting cell proliferation. It is suitable for applications in cancer research and studies related to hormone regulation.

Org-30850 is a potent GnRH receptor antagonist that effectively targets hormone-dependent disorders. Preclinical studies demonstrate its capability to inhibit ovulation in female rats and significantly lower testosterone levels in males for up to 48 hours following a single subcutaneous administration. Administration of daily doses in female rats resulted in suppression of estrous cycles and reduction of uterine and ovarian weights, accompanied by decreased estradiol and FSH serum levels. In male rats, prolonged treatment led to reversible declines in gonadal function and testosterone levels, with nearly complete recovery after treatment cessation. Org-30850 is characterized by minimal injection site irritation, indicating a potentially more favorable therapeutic profile.

[D-Phe2,D-Ala6]-LH-RH is a potent antagonist of luteinizing hormone-releasing hormone (LH-RH). This compound effectively inhibits the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), demonstrating significant antiovulatory activity. It is primarily utilized in reproductive biology research to explore mechanisms of hormone regulation and fertility control.

Kisspeptin 13 functions as an activator of the G protein-coupled receptor GPR54 and the gonadotropin-releasing hormone (GnRH) receptor. This peptide is known to inhibit glucose-induced insulin secretion with an IC50 of 1.2 nM and plays a role in activating the hypothalamic-pituitary-adrenal (HPA) axis, which can induce hyperthermia and influence motor behavior and anxiety in animal models. Additionally, Kisspeptin 13 has been implicated in enhancing memory, suggesting potential applications in Alzheimer's disease research. Its interactions with α2-adrenergic and 5-HT2 serotonin receptors further indicate its antidepressant-like properties.

(Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH (salmon) is a GnRH analog that primarily targets gonadotropin-releasing hormone receptors. It is known to effectively induce ovulation and spawning in farmed fish, making it a valuable tool in aquaculture research. This compound aids in the study of reproductive processes and hormone regulation in aquatic species.

[D-Ala6]-LH-RH is a synthetic analogue of Luteinizing Hormone-Releasing Hormone (LHRH) that functions as a gonadotropin-releasing hormone (GnRH) receptor agonist. This compound is utilized in research to study the regulation of reproductive hormones and to investigate its potential roles in reproductive health and disorders. Its applications include the exploration of mechanisms underlying hormone signaling and the development of therapeutic strategies for conditions such as hormone-dependent cancers.

GnRH-R Antagonist-2 is a selective antagonist of the Gonadotropin-Releasing Hormone Receptor (GnRH-R), exhibiting IC50 values of 43 nM for rat and 88 nM for human receptors. This compound is pivotal in studying hormone-dependent conditions, such as endometriosis and breast and prostate cancers. Its specificity makes it a valuable tool for elucidating the roles of GnRH signaling in various biological contexts and developing targeted therapies.

RS-18286 is a potent luteinizing hormone-releasing hormone (LHRH) antagonist that effectively blocks the pituitary LHRH receptor. By inhibiting this receptor, RS-18286 suppresses the secretion of luteinizing hormone (LH) from the pituitary gland, leading to decreased serum levels of gonadal steroids. This compound can be utilized in research applications related to reproductive biology and endocrinology.

Lutrelin is a luteinizing hormone-releasing hormone (LHRH) agonist that plays a critical role in regulating reproductive hormone levels. This compound has been shown to inhibit the growth of endometrial explants in rat models, making it valuable for research in reproductive biology and the study of endometrial disorders. Its applications extend to both basic research and therapeutic investigations related to hormonal regulation.

A-76154 is a potent LHRH antagonist that functions by inhibiting the action of luteinizing hormone-releasing hormone, thereby regulating gonadotropin secretion. This reduced-size octapeptide is valuable for research applications in reproductive biology and hormone regulation studies. It serves as an important tool for investigating therapeutic interventions in hormone-related disorders and conditions such as hormone-sensitive cancers.

MI-1544 is a potent GnRH antagonist that effectively inhibits pituitary LH release and suppresses gonadal function. This compound is valuable for research applications focused on understanding antifertility mechanisms and exploring therapeutic approaches related to reproductive health.

BIM 21009 is a potent LHRH/GnRH receptor antagonist, primarily targeting the gonadotropin-releasing hormone pathway. It demonstrates significant inhibitory effects on tumor growth, making it an essential tool for research in oncology and reproductive biology. BIM 21009 is valuable for studies focused on hormone-dependent cancers and the modulation of reproductive functions.

Antide acetate is a potent LHRH (luteinizing hormone-releasing hormone) antagonist that effectively modulates hormonal signaling pathways. This compound is primarily utilized in research applications focused on prostate cancer, where it plays a critical role in studying hormone-driven tumor progression and potential therapeutic interventions.

T-98475 is a potent, orally active, non-peptide luteinizing hormone-releasing hormone (LHRH) receptor antagonist, exhibiting an IC50 of 0.2 nM. This compound effectively inhibits LHRH signaling, making it a valuable tool for studies related to reproductive endocrinology and hormone regulation. It is suitable for investigating the role of LHRH in various physiological and pathological conditions, including hormone-responsive cancers and infertility research.

Opigolix is a GnRH receptor antagonist that plays a crucial role in the modulation of gonadotropin release. This compound exhibits significant biological activity in the context of hormonal regulation, making it a valuable tool for research applications related to endometriosis and rheumatoid arthritis. Its mechanism of action involves the inhibition of GnRH signaling pathways, thereby influencing reproductive hormone levels and related physiological processes.